tiprankstipranks
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (HK:1558)
:1558
Hong Kong Market
1558
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H
RESEARCH TOOLSreports

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (1558) Financial Statements

Compare
0 Followers

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H Financial Overview

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H's market cap is currently HK$8.98B. The company's EPS TTM is HK$2.025; its P/E ratio is 5.04; YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H is scheduled to report earnings on March 21, 2025, and the estimated EPS forecast is HK$―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Dec 22Dec 21Dec 20Dec 19
Income Statement
Total Revenue¥ 6.29B¥ 3.74B¥ 913.79M¥ 2.35B¥ 6.22B
Gross Profit¥ 4.99B¥ 2.85B¥ 483.70M¥ 2.00B¥ 5.30B
Operating Income¥ 2.35B¥ 322.72M¥ -458.11M¥ 833.69M¥ 2.53B
EBITDA¥ 2.75B¥ 691.48M¥ -206.55M¥ 950.24M¥ 2.61B
Net Income¥ 1.99B¥ 76.60M¥ -587.65M¥ 839.46M¥ 1.92B
Balance Sheet
Cash & Short-Term Investments¥ 1.69B¥ 1.21B¥ 1.13B¥ 2.04B¥ 2.78B
Total Assets¥ 12.74B¥ 11.89B¥ 10.54B¥ 9.56B¥ 9.91B
Total Debt¥ 2.61B¥ 3.82B¥ 3.19B¥ 3.01B¥ 3.04B
Net Debt¥ 934.91M¥ 2.90B¥ 2.06B¥ 965.69M¥ 256.12M
Total Liabilities¥ 4.81B¥ 5.82B¥ 4.52B¥ 4.46B¥ 5.29B
Stockholders' Equity¥ 7.94B¥ 5.88B¥ 5.81B¥ 4.89B¥ 4.41B
Cash Flow
Free Cash Flow¥ 1.08B¥ 1.13B¥ -1.02B¥ 305.33M¥ 1.22B
Operating Cash Flow¥ 1.67B¥ 1.70B¥ -662.51M¥ 1.30B¥ 1.79B
Investing Cash Flow¥ 554.57M¥ -1.12B¥ -439.11M¥ -2.09B¥ -1.71B
Financing Cash Flow¥ -1.48B¥ -787.03M¥ 187.48M¥ 64.63M¥ 2.10B
Currency in CNY

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H Earnings and Revenue History

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H Debt to Assets

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H Cash Flow

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis